A Review of Analgesic and Anaesthetic Approaches in Local Anaesthetic (Medical) Thoracoscopy [0.03%]
局部麻醉（医学）胸腔镜术的镇痛和麻醉方法概述
Jasandra Sutanto,Duneesha DeFonseka,Bernard Duysinx et al.
Jasandra Sutanto et al.
Pleural disease is a subspecialist area of respiratory medicine, requiring diagnostic and therapeutic interventions. The most invasive pleural procedure is local anaesthetic thoracoscopy (LAT) used in the context of unexplained exudative pl...
Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial [0.03%]
布罗索奇特茋治疗非囊性纤维化支气管扩张的亚洲受试者：ASPEN试验的事后分析
Doreen Addrizzo-Harris,James D Chalmers,Stefano Aliberti et al.
Doreen Addrizzo-Harris et al.
Introduction: In the ASPEN trial, brensocatib, a dipeptidyl peptidase 1 inhibitor, significantly reduced the burden of pulmonary exacerbations versus placebo in participants with bronchiectasis. A prespecified subgroup an...
Respiratory Support in Pediatric Critical and Near-Fatal Asthma: A Narrative Review [0.03%]
儿科重症及近似致命哮喘的呼吸支持：综述
Long Xiang,Herng Lee Tan,Andrew Miller et al.
Long Xiang et al.
Pediatric asthma remains a leading cause of emergency department visits and hospitalizations worldwide. Patients with critical asthma represents a subset of patients requiring respiratory support beyond standard pharmacologic therapy. Manag...
Juan J Zapata-Huizi,Manuela Herrera-Tamayo,Josmar J Ríos-Poveda et al.
Juan J Zapata-Huizi et al.
Sarcoidosis is a systemic granulomatous disorder of unclear origin, most commonly impacting the lungs and mediastinal lymph nodes. Respiratory manifestations occur in most patients and are the main contributors to disease-related morbidity ...
Estimating the Underreporting of COVID-19 Burden in Selected Countries in Asia, Africa, the Middle East, and Latin America in the Post-pandemic Era [0.03%]
估计亚洲、非洲、中东和拉丁美洲部分国家新冠疫情后时代的疾病负担低估情况
Carlos Fernando Mendoza,Julia Spinardi,Iustina Chirila et al.
Carlos Fernando Mendoza et al.
Introduction: The true number of coronavirus disease-19 (COVID-19) cases may be highly underestimated because of reduced efforts to track cases through testing in the postpandemic era. Earlier estimates of this underrepor...
Lydia J Finney,Francesca M Conway,Dheeraj K Sethi
Lydia J Finney
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that is entering a new era in precision medicine. Advances in disease endotyping have challenged the traditional view of COPD as a uniformly neutrophilic disorder and r...
Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials [0.03%]
杜普利尤单抗治疗具有2型炎症的慢性阻塞性肺病的两项III期、随机、双盲、安慰剂对照试验汇总分析小结
Surya P Bhatt,Klaus F Rabe,Nicola A Hanania et al.
Surya P Bhatt et al.
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is usually caused by long-term exposure to harmful substances, such as cigarette smoke, which can lead to inflammation in the airways. Dupilumab is a drug that ...
Lihui Yu,Jingyu Chen
Lihui Yu
Destroyed lung is a radiographic and clinical end-stage condition of chronic pulmonary infection, characterized by irreversible parenchymal destruction and major functional impairment. Medical treatment may control active infection, but est...
Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications [0.03%]
全球pMDI使用情况及欧洲PFAS法规对这些重要吸入药物获取潜力的影响
Janwillem W H Kocks,Tim Harrison,John P Bell et al.
Janwillem W H Kocks et al.
Introduction: Many essential inhaled medicines recommended in guidelines are delivered to the lung via pressurized metered-dose inhalers (pMDIs). Global environmental legislation will lead to phasing out of hydrofluoroalk...
Impact of Single-Inhaler Triple Therapy FF/UMEC/VI on Disease Stability in COPD: A Real-World 12-Month Analysis [0.03%]
单吸入者三联疗法FF/UMEC/VI对慢性阻塞性肺疾病患者病情稳定的影响：一项为期12个月的现实世界分析
Chiara Lupia,Daniela Pastore,Antonio Giacalone et al.
Chiara Lupia et al.
Introduction: Single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic or experience ...